Evidence analysisNovember 11, 2026Health & Science
Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 24, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
Enhertu, whose active substance is trastuzumab deruxtecan, is authorized in the European Union for treating various types of cancer characterized by expression of the HER2 protein. These include:
- HER2-positive metastatic breast cancer or unresectable disease.
- HER2-low and HER2-ultralow metastatic or unresectable breast cancer, particularly following chemotherapy or relapse within six months of adjuvant treatment.
- Advanced non-small cell lung cancer (NSCLC) possessing activating HER2 mutations.
- HER2-positive advanced gastric cancer and gastro-oesophageal junction cancer.
- Other HER2-positive solid tumors lacking surgical options, including metastatic cases.
Enhertu is administered intravenously every three weeks, typically starting with a 90-minute infusion, which may be shortened in subsequent doses if tolerated. It combines two mechanisms of action: trastuzumab, a monoclonal antibody targeting HER2, and deruxtecan, a cytotoxic agent that inhibits topoisomerase I, causing cancer cell death.
What the source claims
The European Medicines Agency (EMA) provides detailed summaries from clinical studies illustrating Enhertu’s efficacy and safety profile:
- In HER2-positive metastatic breast cancer previously treated with two or more HER2-targeted therapies, one study showed about 61% tumor shrinkage in 184 patients.
- Another randomized trial with 524 patients indicated a progression-free survival benefit (18.5 months vs. 5.6 months) compared to trastuzumab emtansine.
- A study combining Enhertu with pertuzumab in treatment-naive metastatic HER2-positive breast cancer suggested a median progression-free survival of 41 months vs. 27 months for standard therapy.
- For HER2-low and HER2-ultralow metastatic breast cancer, improvements in progression-free survival and overall survival were reported versus other treatments or chemotherapy in several studies involving 557 to 866 participants.
- In an ongoing study involving HER2-positive unresectable or metastatic solid tumors lacking alternative options, a response rate of 52% was observed with a median duration of response of 21 months.
- In NSCLC patients with activating HER2 mutations, a 49% response rate and median response duration of 16.8 months were reported in 152 patients after prior platinum-based chemotherapy failure.
- Gastric and gastro-oesophageal junction cancer patients previously treated with trastuzumab showed a 42% tumor response rate with median duration of 8 months in a study of 79 patients.
Reported side effects, generally dependent on cancer type and combination therapy, commonly include nausea, fatigue, vomiting, hair loss, constipation, decreased appetite, and anemia. Infusion reactions such as fever and chills require monitoring.
What may be missing from the usual framing
The EMA’s report provides comprehensive data on efficacy and safety, yet there are areas where further context or detail might be warranted for a more complete understanding:
- Patient selection criteria: The population characteristics beyond HER2 status—such as performance status, comorbidities, or prior therapies—are not extensively detailed here but can impact generalizability.
- Long-term outcomes and quality of life: While survival and response rates are highlighted, information on long-term adverse effects or quality of life assessments is limited.
- Comparative safety profile: Systematic comparisons of adverse events versus alternative therapies, particularly regarding severity and long-term risks, are not fully presented.
- Cost and accessibility: The dossier does not address economic aspects or patient access variations across the EU, which affect real-world impact.
- Mechanisms of resistance: Emerging scientific discussions around tumor resistance mechanisms to HER2-targeted agents including Enhertu are not covered.
Competing evidence or uncertainty
While the EMA report references controlled or ongoing clinical studies supporting Enhertu’s use, some areas have incomplete evidence or require further research:
- Non-comparative studies: Some indications, such as HER2-positive solid tumors other than breast, lung and gastric cancers, are supported mainly by single-arm studies without comparator arms, limiting assessment of relative effectiveness.
- Broader real-world evidence: Post-marketing data on effectiveness and safety in broader, more diverse patient populations may yield results differing from clinical trial populations.
- Longer-term survival data: While promising progression-free survival improvements are documented, overall survival benefits and their durability in some settings remain under further investigation.
- Side effect management: Detailed protocols and outcomes related to managing serious adverse events like interstitial lung disease are not fully delineated.
- HER2-low and ultraslow categories: The clinical and biological definitions of HER2-low and ultralow breast cancer are evolving, and their consistent identification and response prediction are areas of ongoing research.
Why it matters
The EMA’s authorization and supporting evidence for Enhertu represent an important expansion of targeted therapy options for patients with various HER2-expressing malignancies, including some cancers with limited prior options. The dual-action mechanism combining antibody targeting and cytotoxic delivery exemplifies progress in personalized oncology treatments.
Improved progression-free and overall survival endpoints have potential to reduce disease burden and improve patient outlook. However, acknowledging the nuances in efficacy, adverse effects, and patient selection is critical for informed clinical decision-making and patient counseling.
Understanding what is currently known—and where evidence is limited—allows clinicians, patients, and policymakers to weigh benefits against risks and costs, and to prioritize further research.
What to verify next
Readers seeking to deepen understanding of Enhertu’s clinical impact should consult the original EMA source for detailed study protocols, patient demographics, and full adverse event profiles. Further areas to explore include:
- Long-term outcomes and quality of life assessments from ongoing and future clinical trials.
- Real-world effectiveness and safety data in broader patient populations post-authorization.
- Detailed information on toxicity management and clinical guidelines for side effect mitigation.
- Health economic evaluations to understand cost-effectiveness and access disparities across different healthcare systems.
- Clarification and standardization of the HER2-low and ultralow tumor categories for appropriate patient selection.
Verification through peer-reviewed publications, independent clinical reviews, and ongoing post-marketing surveillance will be key to refining understanding of Enhertu’s role in cancer treatment.
Note: This dossier summarizes evidence up to November 2026 as per the European Medicines Agency public assessment report and is not a substitute for professional medical advice. Consult healthcare providers and the original EMA documentation for personalized clinical decisions.
Source & verification
Primary source: What's new · November 11, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…